Clovis Oncology's cancer drug Rubraca succeeds in key study (AZN)

Xavier Trudeau
Juin 19, 2017

The firm issued an outperform rating and a $85.00 price target on the biopharmaceutical company's stock. Bank of America Corporation's target price would suggest a potential upside of 25.06% from the company's current price.

A number of other equities research analysts also recently weighed in on the stock. Samlyn Capital Ltd Liability has 0.91% invested in Clovis Oncology Inc (NASDAQ:CLVS) for 903,800 shares. They noted that the move was a valuation call.

The stock of Clovis Oncology Inc (NASDAQ:CLVS) hit a new 52-week high and has $93.95 target or 6.00% above today's $88.63 share price. J P Morgan Chase & Co reissued a "hold" rating on shares of Clovis Oncology in a research report on Wednesday, March 15th. $48.31's average target is -17.85% below currents $58.81 stock price.

Clovis Oncology (NASDAQ:CLVS) opened at 59.97 on Tuesday. The consensus recommendation by Thomson Reuters analysts is Outperform and their mean rating for the stock is 2.17 on scale of 1-5. The company has market cap of $2.48 billion.

05/17/2017 - Clovis Oncology, Inc. was upgraded to " by analysts at JP Morgan. The stock has a 50 day moving average of $54.46 and a 200 day moving average of $55.14.

Clovis Oncology (NASDAQ:CLVS) last announced its earnings results on Wednesday, May 3rd. After $-1.33 actual earnings per share reported by Clovis Oncology Inc for the previous quarter, Wall Street now forecasts 3.01% negative EPS growth. The company had revenue of $7.05 million during the quarter, compared to analyst estimates of $6.04 million.

WARNING: This piece of content was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another publication, it was illegally stolen and republished in violation of US & global trademark & copyright law. Taking a look back at some historical performance numbers for Clovis Oncology, Inc. The stock was sold at an average price of $47.39, for a total transaction of $142,170.00. Following the sale, the insider now directly owns 203,583 shares of the company's stock, valued at approximately $9,647,798.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. FMR LLC now owns 1,816,859 shares of the biopharmaceutical company's stock worth $115,679,000 after buying an additional 1,327,703 shares during the period. Ivers-read now owns $11,572,780 of stock per an SEC filing yesterday. Regardless, closing prices are a useful tool that investors use to quantify changes in stock prices over time. Sivik Glob Healthcare Limited has 0.32% invested in Clovis Oncology Inc (NASDAQ:CLVS) for 15,000 shares. Palo Alto Investors LLC now owns 3,894,963 shares of the biopharmaceutical company's stock worth $247,992,000 after buying an additional 90,875 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in Clovis Oncology by 9.8% in the fourth quarter. Finally, Endurant Capital Management LP increased its stake in Clovis Oncology by 73.1% in the first quarter. Vanguard Group Inc. now owns 3,285,195 shares of the biopharmaceutical company's stock valued at $209,169,000 after buying an additional 662,969 shares during the last quarter. Institutional investors and hedge funds own 97.55% of the company's stock.

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other global markets. The Company's product candidates include Rociletinib, Rubraca and Lucitanib. FDA last December granted rucaparib camsylate accelerated approval in patients whose tumors have a mutation called BRCA, and whose disease had advanced despite two or more rounds of chemotherapy.

D'autres rapports CampDesrEcrues

Discuter de cet article